A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Sulindac has been studied across 18 research domains including 🔬 Inflammation, 🔬 Oncology, 🦴 Bone & Joint, 🫁 Liver & Detox, 🫘 Kidney. The primary research focus is 🔬 Inflammation with 41% of studies addressing this area.
The following compounds share molecular targets with Sulindac, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Sulindac is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.